Modulation of the immune microenvironment in high risk DCIS by intralesional injection of anti-PD-1 (pembrolizumab)-MedSci.cn

Modulation of the immune microenvironment in high risk DCIS by intralesional injection of anti-PD-1 (pembrolizumab)

Campbell, MJ; McCune, E; Rothschild, H; Bolen, J; VandenBerg, S; Chien, J; Wong, J; Esserman, L

CANCER RESEARCH, 2019; 79 (4):

科室
- - 订阅+
  - 更多科室
工具
服务